BLUE:NSD-bluebird bio, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 30.48

Change

0.00 (0.00)%

Market Cap

USD 2.06B

Volume

1.08M

Average Target Price

USD 43.77 (+43.60%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

N/A

USD52.92B 16.28 12.68
BNTX BioNTech SE

N/A

USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

N/A

USD28.69B N/A N/A
SGEN Seagen Inc

N/A

USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

N/A

USD24.87B 22.60 14.92
GMAB Genmab A/S

N/A

USD24.05B 26.59 3.06
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BLUE

Symbol Name Weight Mer Price(Change) Market Cap
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

N/A

USD0.06B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.56% 18% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.56% 18% F 9% F
Trailing 12 Months  
Capital Gain -48.58% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.58% 11% F 4% F
Trailing 5 Years  
Capital Gain -25.29% 44% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.29% 44% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain 15.41% 52% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.41% 52% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 78.41% 38% F 21% F
Risk Adjusted Return 19.65% 47% F 40% F
Market Capitalization 2.06B 83% B 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.48 92% A- 74% C
Price / Cash Flow Ratio -4.37 33% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -53.59% 54% F 21% F
Return on Invested Capital -47.74% 51% F 17% F
Return on Assets -25.81% 50% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.77 51% F 36% F
Short Percent 14.30% 16% F 13% F
Beta 1.74 30% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.